glp 1 trial Medscape | The investigational triple GLP-1/GIP/glucagon receptor agonist retatrutide produced significant weight loss and A1c reduction in people What is the pipeline for

Published today in JAMA Health Forum, the study found that many weight-loss clinics and medical spas continue to sell compounded versions of GLP-1 medications such as semaglutide and tirzepatide

The experimental protocol was authorized by the Institutional Ethics Committee of VetAgro Sup (CEEA 18, project number 2066) and the French Ministry (APAFIS#27797-2020100516408472), and we have complied with all relevant ethical regulations for animal use

All medications are HSA/FSA eligible, available nationwide without insurance, and require no membership fees

GLP-1 drugs are not a substitute for established substance use disorder treatments, and any changes in substance use patterns should be monitored by healthcare providers